CONFIDENTIAL USE ONLY – DO NOT DISTRIBUTE

Strictly Confidential: Private Use Only

250+ Employees Globally

( 69 R&D & 42 Commercial)

Committed to Bringing Global Best-in-Class Propriety Therapeutic Products

2 Indications

1stCommercialized Product 2 NDA ongoing

- US PDUFA March 2021

- Korea NDA to be April 2021

2 Marketing Authorizations

- Europe (EMA) in 2019

- Taiwan in 2020

Global Phase 3 Trials

ET studies in US, CN, JP, KR, TW

Besremi®(Ropeginterferon alfa-2b)

- Polycythemia vera (PV)

- Essential thrombocythemia (ET)

Strictly Confidential: Private Use Only

PharmaEssentia

Development

Patients

Discovery

Made In Taiwan

Fully Integrated Global Biopharmaceutical Company with End-to-End Capabilities

Strictly Confidential: Private Use Only

Best-in-Class Management Team with ~75yr+ experience

25+ yr Experience:

Ionis Pharmaceuticals,

Food and Drug

Administration (FDA)

PhD, University of Michigan

25+ yr Experience:

Biogen Inc.,

Monsanto - Searle

PhD, University of Missouri

Postdoc, University of Michigan

2019 Humanitarian Honoree (MPN CR&T Fund)

25+ yr Experience:

Optimer Pharmaceuticals, Amgen Inc.,

Ligand Pharmaceutical,

Array Biopharma.

PhD, University of Pennsylvania

Ko-Chung Lin, PhDFounder & CEO

Ching-Leou Teng, PhDChairwoman

Jack Hwang, PhDGeneral Manager

5

Increasing Global Footprint from Taiwan to Worldwide

CONFIDENTIAL – DRAFT – FOR INTERNAL USE ONLY – DO NOT DISTRIBUTE

Taiwan

USA

European Union Partner

Hong Kong

China South Korea

Japan

Taipei - Headquarter

• Nankang site: GMP certified PEGylation plant• Taichung site:

• GMP certified manufacturing/biologics plant

• Filled and finished plant

Two cGMP-compliant Manufacturing Facilities in Taiwan

Senior Field Management – Extensive Experience in Hematology, Oncology and Rare Diseases

27%

17%

56%

R&D Commercial Other

250+employees

6

Global Executives with Proven Track of Execution

China General Manager U.S. General Manager Korea General ManagerJapan General Manager

• AGTech, BearingPoint Consulting,

• Biogen Inc.

• Shanghai Institute of Pharmaceutical Ind.

• MBA, Babson College

• MS, Northeastern University

• Shire - Vice President, Global Product Strategy Lead Hemophilia

• Baxalta - Vice President, Global Hemophilia Marketing

• Baxter - VP, Global Hemophilia Marketing

• Vertex - Launch their hepatitis - C drug, Incivik, which reached to $1.0Bn in sales within 8 months

• Novartis Korea

• Executive Advisor for Country President, Korea

• Country President, Korea

• Country President, Taiwan

• General Manager, Oncology Business Unit, Korea

• Shire Japan KK,

• Novartis Pharmaceuticals

• Janssen Pharmaceutical

• Astellas Pharmaceutical

• BA, Kochi University, Japan

Meredith Manning, MBAWarren ShenKatsuya Yonezu Haksun Moon

Strictly Confidential: Private Use Only

Strong Leadership Team with Extensive Biopharma Experience

Tony ChambersVice President,

Sales & Market Access

Danielle HoltschlagSenior Director,

Sales Operations

Kate ReedyVice President,

Marketing and Business Intelligence

Craig ZimmermanVice President,

Clinical Development and Regulatory

Sam LinSenior Director, Business Operations and Strategy

Delphine El MehdiDirector, Medical Affairs

Meredith Manning, MBAU.S. General Manager

Ray Urbanski, M.D., Ph.DHead of Medical Affairs

and Clinical Development

8

Our 1st product Besremi®(Ropeginterferon alfa-2b)

Strictly Confidential: Private Use Only

Single form formulation leads to longer half-life and lower toxicity

Notes: HBV – Hepatitis B virus; HCV – Hepatitis C virus

Pegasys*PEG Interferon alfa-2a, for HCV & HBV

Besremi®

Ropeginterferon alfa-2b / P1101

K84K122

P1101 Predominant

form

Clinical Proven Results

• Long-acting (2x duration)

• Less frequent dosing

• once every two weeks (reduced by half)

• Less serious adverse events

• Highest maximum tolerated dose (MTD)

Multiple therapeutic areas

Best-in-Class PEGylated Interferon : Ropeginterferon-Alfa-2b

*Pegasys will be off the US market by end of 2021

Strictly Confidential: Private Use Only

US Marketing Advantage - UnprecedentedInterferon stated as 1st line and 2nd line treatment in NCCN Guidelines before approval

1 Adapted from NCCN Guideline (May 21st, 2020)2 Inadequate response or loss of response

• Monitor

• Manage CV risk factors

• Aspirin

• Phlebotomy

• Hydroxyurea OR

Peginterferon alfa-2a

Treatment failure2

• Clinical Trial

• Ruxolitinib

• Hydroxyurea

• Peginterferon alfa-2a

• Busulphan

IF

2nd line treatmentInitial treatment (1st line)

High-risk PV patient1

High, complete hematologic response

Low toxicity Non-mutagenicLess frequent dosing

schedule

Disease modification to slow or halt disease

progression

Besremi Meeting Key Unmet Needs for PV Treatment

11

~100,000Patients diagnosed with

PV in the U.S.3

(~158,000 people livingwith PV in U.S.1,2)

~60 YEARSAverage age of onset4,

diagnosed often by routine blood tests due to vague, non-descript symptoms

Primary symptoms5

Fatigue

Aquagenic pruritis

Headaches

Reddened Face

Weight Loss

Freq

uen

cy o

f O

ccu

rren

ce

2nd lineCytoreductive therapy

Second line: patients currently receiving other cytoreductive agents post failure of HU

1st lineCytoreductive therapy

First line: main treatment goal to focus on short-term CV risk and symptoms relief

Phlebotomy / Aspirin>40% of diagnosed patients are managed with aspirin/phlebotomy

CONVENTIONAL APPROACH TO CARE BASED ON AVAILABLE THERAPEUTIC OPTIONS

Most physicians treat <10 PV

patients

Volume of patients who present with elevated HCT

and are asymptomatic4

~67% ASYMPTOMATIC

Sources: 1 Population - US Census Pop Clock, accessed June 8, 2020, 2 Prevalence rate (2010 marketscan assumption) - Mehta et al 3 Data on File 4 National Organization for Rare Disorders (NORD). Polycythemia Vera. https://rarediseases.org/rare-diseases/polycythemia-vera/. Accessed May 27, 2020. 5 Polycythemia Vera Patient Journey market research by BluePrint Research Group (May 2020)

U.S. market today: Opportunity to advance care in PV

~12,000 Physicians involved in MPN patient care

• MPN specialists• Academic centers• Community oncologists

Strictly Confidential: Private Use Only

Attractive US Market Opportunities in MPNMarket Opportunity

Strictly Confidential: Private Use Only

PDUFA Date - March 13th , 2021

Counting Down for U.S. Marketing Approval

Mar Apr May June July Aug Sep Oct Nov Dec Jan FebOur

ProgressMar

March 13th May 12th

PDUFA March 13th , 2021

month 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th

2020 2021

Strictly Confidential: Private Use Only

Available in 16 European Countries ~ € 2,500/250mcg

Belarus

Ukraine

Germany

France

Italy

SpainPortugal

Ireland United Kingdom

Greece

SwedenFinland

Denmark

Estonia

Latvia

Lithuania

Poland

Romania

Hungary

Czech Slovakia

Austria

Bulgaria

Netherlands

Belgium

Malta

Luxembourg

Croatia

Slovenia

Cyprus

Iceland

Norway

Liechtenstein

Switzerland

Russia

Source: Denmark Pricing: Danish Medicines Agency (link)Slovenia: Ministry of Health (link)Italy: Italian Medicines Agency (AIFA) (link) *Ireland: Health Products Regulatory Authority (link)*

1. Germany € 2,708 (250mcg)

2. Austria € 2,708 (250mcg)

3. Slovenia € 2,025 (250mcg)

4. Denmark € 3,178 (250mcg)

5. Italy € 4,450 (500mcg)

6. Ireland

7. United Kingdom

8. The Czech Republic

9. Hungary

10. France

11. Greece

12. Switzerland € 2,557 (250mcg)

13. Sweden € 2,390 (250mcg)

14. Liechtenstein

15. Finland € 2,876 (250mcg)

16. Norway

Kazakhstan

Turkey

Georgia

AzerbaijanArmenia

Belarus

Ukraine

Moldova

European Union (EU)

Besremi listed countries

*Dosing frequency: Bi-weekly

15

2nd Indication: Essential Thrombocythemia (ET)

Strictly Confidential: Private Use Only Page 16

Phase III Global Pivotal ET study ongoingFiling expected in early 2023

Primary Endpoint

Randomized, open-label, active-controlled study designed to compare the efficacy and safety with ANA (n=160)

• Peripheral blood count remission (months 9 and 12)• Improvement or non-progression in disease-related signs

(months 9 and 12)• Large Symptoms improvement• Absence of hemorrhagic or thrombotic events

StudyType

Second-Line ET Study vs Anagrelide (NCT04285086)

Reference：1. Tefferi (2018) Blood Cancer Journal 8, 2

Analysis(9 mo)

Adult patients with high-risk ET

Eligible PV patients based on WHO 2016 criteria

Patients who were treated with HU or HU resistant/tolerant

Randomization Screen(1 mo)

Ropeginterferon, Q2W, SC

Anagrelide, Daily, oral

Treatment(12 mo)

Analysis(12 mo)

Follow-up(1 mo)

Strictly Confidential: Private Use Only

Global ET Trial Supported by Strong Medical Professionals

Albert Qin, M.D. Ph.D.Chief Medical Officer

SymBio Pharmaceuticals, ImmunoGen, Biogen, Pfizer

PhD., Harvard University

Oleh Zagrijtschuk, M.D. Ph.D.Therapeutic Head, U.S.

Yi-Wen Huang, M.D. Ph.D.Senior Director, Taiwan

Toshiaki Sato, M.D. Ph.D.Chief Medical Director, Japan

Kee-Woo Kim, M.D. Ph. D.Medical Director, Korea

M.D., Medical University of Vienna

MBA, WU Executive Academy

Cathay General Hospital

M.D., China Medical University

Ph.D., NTU

Johns Hopkins University, Post-doc

Oita Medical University, Japan

Ph.D., The Catholic University of Korea

M.D., SoonchunhyangUniversity, Korea

Strictly Confidential: Private Use Only

Besremi® : Key Milestones & Future Growth Strategy

2019 2020 2021 2022 2023

EU EU EU EU EU

TW TW

US

TW

US

KR

TW

US

KR

JP

KR

JP

CN

TW

US

KR

JP

CN

PV

ET

Marketing Authorizations

Extend PV approval territories

Expand Ropeginterferon indications and strengthen our collaboration with partners

Enrich pipeline through

1) proprietary science team;

2) collaboration; or

3) acquisition

Obtained marketing approval of Ropeginterferon in polycythemia vera in EU and Taiwan

Strictly Confidential: Private Use Only

Tremendous Indication Expansion Opportunities

Solid Tumor• Multiple Myeloma• Bladder Cancer• Malignant Melanoma• Kaposi’s Sarcoma• Squamous cell carcinoma of the conjunctiva• Carcinoid Syndrome

Leukemia• Chronic Myelocytic Leukemia• Hairy Cell Leukemia• Adult T-cell Leukemia (Japan)

Source: WebMD.com

Lymphoma

• Follicular Lymphoma

• Cutaneous T-cell Lymphoma

• Mycosis fungoides

Strictly Confidential: Private Use Only

Concentration Technology Indication MarketPre-

ClinicalProof of Concept Pivotal Regulatory Approval

HematologyP1101

PV

EU

TW

US, KR

JP, CN

ET Global

Adult T-Cell Leukemia JP, TW, CN

Next Gen.of P1101 MPN Global

Oncology

P1101 + anti PD-1 HCC Global

Oraxol Breast Cancer TW, SG, VN

Oraxol +Ramucirumab Gastric Cancer TW, SG, VN

P1101 Solid Tumors Global

Infectious P1101 HDV US, EU, TW

DermatologyKX01 Psoriasis TW, CN, MY, SG

KX01Actinic

Keratosis TW

Solid Pipeline Fueling Next Wave of Growth

PDUFA Q1, 2021

21

Thank YouPharmaEssentia